$570 Million is the total value of Avoro Capital Advisors LLC's 48 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 30.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SRPT | Sell | SAREPTA THERAPUTICS INC | $84,126,000 | +212.4% | 1,369,909 | -3.0% | 14.76% | +146.7% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $38,832,000 | +15.3% | 419,712 | -3.1% | 6.81% | -9.0% |
| LBIO | Sell | LION BIOTECHNOLOGIES INC | $35,038,000 | -0.3% | 4,257,347 | -1.9% | 6.15% | -21.3% |
| TSRO | Sell | TESARO INC | $27,837,000 | -35.6% | 277,703 | -46.0% | 4.88% | -49.1% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $27,305,000 | +35.2% | 3,689,857 | -0.2% | 4.79% | +6.8% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $24,843,000 | +7.3% | 490,582 | -3.7% | 4.36% | -15.3% |
| IMMU | Sell | IMMUNOMEDICS INC | $23,869,000 | +20.2% | 7,344,177 | -14.2% | 4.19% | -5.1% |
| BMY | Sell | BRISTOL MYERS SQUIBB CO. | $21,561,000 | -34.2% | 399,875 | -10.2% | 3.78% | -48.0% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS | $20,037,000 | +25.3% | 869,263 | -9.8% | 3.52% | -1.0% |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $11,852,000 | +27.9% | 1,531,273 | -7.5% | 2.08% | +1.0% |
| CASC | Sell | CASCADIAN THERAPEUTICS INC | $9,203,000 | +69.9% | 5,611,323 | -2.3% | 1.62% | +34.1% |
| SRPT | Sell | SAREPTA THERAPUTICS INCcall | $6,033,000 | +131.8% | 190,000 | -69.6% | 1.06% | +83.2% |
| ONS | Sell | ONCOBIOLOGICS INC | $1,916,000 | +20.7% | 450,872 | -3.4% | 0.34% | -4.8% |
| VCEL | Sell | VERICEL CORP | $604,000 | +5.2% | 215,744 | -15.4% | 0.11% | -17.2% |
| IMMU | Sell | IMMUNOMEDICS INCcall | $53,000 | -17.2% | 300,800 | -33.7% | 0.01% | -35.7% |
| SRPT | Sell | SAREPTA THERAPUTICS INCput | $2,000 | -99.9% | 75,600 | -94.3% | 0.00% | -100.0% |
| Exit | ISh RUSSELL 2000 ETFput | $0 | – | -50,000 | -100.0% | -0.00% | – | |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -70,000 | -100.0% | -0.25% | – |
| CYTK | Exit | CYTOKINETICS INC. | $0 | – | -503,900 | -100.0% | -1.06% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -108,500 | -100.0% | -2.01% | – |
| RLYP | Exit | RELYPSA INC | $0 | – | -613,300 | -100.0% | -2.52% | – |
| MDVN | Exit | MEDIVATION INC | $0 | – | -279,700 | -100.0% | -3.75% | – |
| CPXX | Exit | CELATOR PHARMACEUTICALS INC. | $0 | – | -1,124,666 | -100.0% | -7.54% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.